Table 3 Correlation between FAM64A expression and the clinicopathological characters of patients with PCa (IHC).
From: FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer
Clinico-pathologic variables | No. of cases | FAM64A expression | χ2 | Ρ | |
|---|---|---|---|---|---|
low | high | ||||
All cases | 97 | 43(44.3%) | 54(55.7%) | ||
Age | |||||
≤60 | 4(4.1%) | 1(1.0%) | 3(3.1%) | 0.66121 | 0.4162 |
>60 | 93(95.9%) | 42(43.3%) | 51(52.6%) | ||
Tumor stage | |||||
T1–T2 | 14(15.4%) | 5(5.5%) | 9(9.9%) | 0.45621 | 0.4994 |
T3–T4 | 77(84.6%) | 35(38.5%) | 42(46.1%) | ||
Lymph nodes status | |||||
Negative | 72(79.1%) | 37(40.6%) | 35(38.5%) | 5.5891 | 0.0181* |
Positive | 19(20.9%) | 4(4.4%) | 15(16.5%) | ||
Gleason score | |||||
6–7 | 51(55.6%) | 21(21.6%) | 30(34.0%) | 0.43331 | 0.5104 |
8–10 | 46(47.4%) | 22(22.7%) | 24(24.7%) | ||
Ki-67 | |||||
<10 | 74(79.6%) | 39(42.0%) | 35(37.6%) | 6.0921 | 0.0136* |
>10 | 19(20.4%) | 4(4.3%) | 15(16.1%) | ||
P53 | |||||
+ | 21(23.9%) | 7(8.0%) | 14(15.9%) | 1.3491 | 0.2455 |
− | 67(76.1%) | 32(36.3%) | 35(39.8%) | ||
PSA | |||||
+ | 81(85.3%) | 38(40.0%) | 43(45.3%) | 0.079001 | 0.7787 |
− | 14(14.7%) | 6(6.3%) | 8(8.4%) | ||
SMA | |||||
+ | 11(13.6%) | 5(6.2%) | 6(7.4%) | 0.0052601 | 0.9422 |
− | 70(86.4%) | 31(38.3%) | 39(48.1%) | ||
TOPO-II | |||||
+ | 65(81.25%) | 23(28.75%) | 42(54.5%) | 9.8581 | 0.0017** |
− | 15(18.75%) | 12(15%) | 3(3.75%) | ||
ERG | |||||
+ | 20(25.6%) | 3(3.8%) | 17(21.8%) | 8.9411 | 0.0028** |
− | 58(74.4%) | 31(39.8%) | 27(34.6%) | ||
